Related Experiment Video

Updated: Feb 12, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

661

[THE ROLE OF MARKER FIBROSIS ST2 AND ANGIOTENZINOGEN GENE POLYMORPHISM IN HEART FAILURE PROGRESSING IN PATIENTS WITH

I Rudyk1, O Medentseva1

  • 1SI "National Institute of Therapy named after L.T.Maloy NAMS of Ukraine", Ukraine.

Georgian Medical News
|March 27, 2018
PubMed

Insights

Patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2DM) carrying specific ATG gene variants (TT+MT) show higher ST2 levels and increased cardiovascular event risk. This highlights genetic factors in HFpEF progression.

Area of Science:

  • Cardiology
  • Genetics
  • Metabolic Disorders

Background:

  • Heart failure (HF) prognosis is poor, especially in subgroups like those with type 2 diabetes (T2DM).
  • The M235T polymorphism in the angiotensinogen (AGT) gene (rs699) is linked to hypertension, coronary heart disease, atrial fibrillation, and HF risk.
  • ST2 is an emerging biomarker for cardiac fibrosis.

Purpose of the Study:

  • To investigate the role of the ST2 biomarker and AGT gene M235T polymorphism in chronic heart failure (CHF) progression.
  • To assess their impact on adverse cardiovascular events in patients with T2DM.

Main Methods:

  • Analysis of ST2 levels and AGT gene M235T polymorphism (rs699).
  • Observation of cardiovascular events over 24 months in patients with HFpEF and T2DM.
  • Comparison between different AGT genotypes (TT+MT vs. MM).

Main Results:

  • Patients with HFpEF and T2DM with the TT+MT genotype exhibited higher ST2 levels.
  • These patients also had a greater probability of adverse cardiovascular events within 24 months compared to MM genotype carriers.

Conclusions:

  • The AGT TT+MT genotype is associated with elevated ST2 levels and increased cardiovascular risk in HFpEF patients with T2DM.
  • ST2 and AGT M235T polymorphism are valuable indicators for predicting adverse outcomes in this patient subgroup.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395